Literature DB >> 7494298

Cellular factors required for papillomavirus DNA replication.

T Melendy1, J Sedman, A Stenlund.   

Abstract

In vitro replication of papillomavirus DNA has been carried out with a combination of purified proteins and partially purified extracts made from human cells. DNA synthesis requires the viral E1 protein and the papillomavirus origin of replication. The E2 protein stimulates DNA synthesis in a binding site-independent manner. Papillomavirus DNA replication is also dependent on the cellular factors replication protein A, replication factor C, and proliferating-cell nuclear antigen as well as a phosphocellulose column fraction (IIA). Fraction IIA contains DNA polymerase alpha-primase and DNA polymerase delta. Both of these polymerases are essential for papillomavirus DNA replication in vitro. However, unlike the case with T-antigen-dependent replication from the simian virus 40 origin, purified DNA polymerase alpha-primase and delta cannot efficiently replace fraction IIA in the replication reaction. Hence, additional cellular factors seem to be required for papillomavirus DNA replication. Interestingly, replication factor C and proliferating-cell nuclear antigen are more stringently required for DNA synthesis in the papillomavirus system than in the simian virus 40 in vitro system. These distinctions indicate that there must be mechanistic differences between the DNA replication systems of papillomavirus and simian virus 40.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494298      PMCID: PMC189730     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  96 in total

Review 1.  Replication of plasmids derived from bovine papilloma virus type 1 and Epstein-Barr virus in cells in culture.

Authors:  J Mecsas; B Sugden
Journal:  Annu Rev Cell Biol       Date:  1987

Review 2.  The in vitro replication of DNA containing the SV40 origin.

Authors:  J Hurwitz; F B Dean; A D Kwong; S H Lee
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

3.  p53 and DNA polymerase alpha compete for binding to SV40 T antigen.

Authors:  J V Gannon; D P Lane
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

4.  The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro.

Authors:  G Prelich; M Kostura; D R Marshak; M B Mathews; B Stillman
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

5.  Replication of simian virus 40 origin-containing DNA in vitro with purified proteins.

Authors:  C R Wobbe; L Weissbach; J A Borowiec; F B Dean; Y Murakami; P Bullock; J Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

6.  Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro.

Authors:  L Yang; M S Wold; J J Li; T J Kelly; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

7.  Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein.

Authors:  G Prelich; C K Tan; M Kostura; M B Mathews; A G So; K M Downey; B Stillman
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

8.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

9.  DNA polymerase III from Saccharomyces cerevisiae. I. Purification and characterization.

Authors:  G A Bauer; H M Heller; P M Burgers
Journal:  J Biol Chem       Date:  1988-01-15       Impact factor: 5.157

10.  Yeast DNA polymerase--DNA primase complex; cloning of PRI 1, a single essential gene related to DNA primase activity.

Authors:  G Lucchini; S Francesconi; M Foiani; G Badaracco; P Plevani
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  56 in total

1.  The replicator of the Epstein-Barr virus latent cycle origin of DNA replication, oriP, is composed of multiple functional elements.

Authors:  M D Koons; S Van Scoy; J Hearing
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins.

Authors:  T Yasugi; M Vidal; H Sakai; P M Howley; J D Benson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Identification of a short, hydrophilic amino acid sequence critical for origin recognition by the bovine papillomavirus E1 protein.

Authors:  A Gonzalez; C Bazaldua-Hernandez; M West; K Woytek; V G Wilson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide.

Authors:  Michaël Lehoux; Amélie Fradet-Turcotte; Mathieu Lussier-Price; James G Omichinski; Jacques Archambault
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle.

Authors:  E R Flores; P F Lambert
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 6.  Replication and partitioning of papillomavirus genomes.

Authors:  Alison A McBride
Journal:  Adv Virus Res       Date:  2008       Impact factor: 9.937

Review 7.  The E1 proteins.

Authors:  Monika Bergvall; Thomas Melendy; Jacques Archambault
Journal:  Virology       Date:  2013-09-10       Impact factor: 3.616

8.  Characterization of the DNA-binding domain of the bovine papillomavirus replication initiator E1.

Authors:  G Chen; A Stenlund
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 9.  Targeting human papillomavirus genome replication for antiviral drug discovery.

Authors:  Jacques Archambault; Thomas Melendy
Journal:  Antivir Ther       Date:  2013-04-24

10.  Viral trans-factor independent replication of human papillomavirus genomes.

Authors:  Daraporn Pittayakhajonwut; Peter C Angeletti
Journal:  Virol J       Date:  2010-06-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.